Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
New product line to address the challenge of restrictions on use of plastic straws
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The minister exhorted the pharmaceutical sector to prepare a plan for the next 25 years
The company also plans to expand the facility
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
Subscribe To Our Newsletter & Stay Updated
